(July 15, 2021, 4:53 PM EDT) -- KANSAS CITY, Kan. — Pfizer Inc. and two related defendants have agreed to a $345 million class settlement of claims by consumers and third-party payers that they overpriced the EpiPen epinephrine autoinjector and engaged in anti-competitive behavior, according to a settlement agreement and approval motion filed July 14 in Kansas federal court....